

## **Adult CIRB - Late Phase Emphasis Meeting Agenda**

**December 17, 2020**

---

### **I Continuing Review**

**EA5182**, Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) (Protocol Version Date 07/22/20)

---

### **II Continuing Review**

**EA8185**, Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in clinical Stage III, Node Positive bladder cancer (INSPIRE) (Protocol Version Date 07/02/20)

---

### **III Continuing Review**

**NRG-GI005**, Phase II/III Study of Circulating tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) (Protocol Version Date 09/16/19)

---

### **IV Continuing Review**

**NRG-GY020**, A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer (Protocol Version Date 09/10/20)

---

### **V New Study - Initial Review**

**A021901**, Randomized Phase II Trial of Lutetium Lu 177 Dotatate versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors (Protocol Version



FOR THE NATIONAL CANCER INSTITUTE

Date 11/06/20)

---

---

---

## **VI New Study - Initial Review**

**EA3191**, A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features (Protocol Version Date 11/19/20)

---

---

## **VII Amendment**

**EAA181**, Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation (Protocol Version Date 11/18/20)

---